These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 35332262)
1. Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas. Hong L; Shi ZF; Li KK; Wang WW; Yang RR; Kwan JS; Chen H; Li FC; Liu XZ; Chan DT; Li WC; Zhang ZY; Mao Y; Ng HK Lab Invest; 2022 Jul; 102(7):731-740. PubMed ID: 35332262 [TBL] [Abstract][Full Text] [Related]
2. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults. Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072 [TBL] [Abstract][Full Text] [Related]
3. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas. Liu EM; Shi ZF; Li KK; Malta TM; Chung NY; Chen H; Chan JY; Poon MF; Kwan JS; Chan DT; Noushmehr H; Mao Y; Ng HK Brain Pathol; 2022 Nov; 32(6):e13107. PubMed ID: 35815721 [TBL] [Abstract][Full Text] [Related]
4. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446 [TBL] [Abstract][Full Text] [Related]
5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105 [TBL] [Abstract][Full Text] [Related]
7. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499 [TBL] [Abstract][Full Text] [Related]
8. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198 [TBL] [Abstract][Full Text] [Related]
9. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020 [TBL] [Abstract][Full Text] [Related]
10. Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases. Kibe Y; Ohka F; Aoki K; Yamaguchi J; Motomura K; Ito E; Takeuchi K; Nagata Y; Ito S; Mizutani N; Shiba Y; Maeda S; Nishikawa T; Shimizu H; Saito R Acta Neuropathol Commun; 2024 Apr; 12(1):57. PubMed ID: 38605367 [TBL] [Abstract][Full Text] [Related]
11. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808 [TBL] [Abstract][Full Text] [Related]
12. Glioblastomas harboring gene fusions detected by next-generation sequencing. Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533 [TBL] [Abstract][Full Text] [Related]
13. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Korshunov A; Ryzhova M; Hovestadt V; Bender S; Sturm D; Capper D; Meyer J; Schrimpf D; Kool M; Northcott PA; Zheludkova O; Milde T; Witt O; Kulozik AE; Reifenberger G; Jabado N; Perry A; Lichter P; von Deimling A; Pfister SM; Jones DT Acta Neuropathol; 2015 May; 129(5):669-78. PubMed ID: 25752754 [TBL] [Abstract][Full Text] [Related]
14. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Korshunov A; Schrimpf D; Ryzhova M; Sturm D; Chavez L; Hovestadt V; Sharma T; Habel A; Burford A; Jones C; Zheludkova O; Kumirova E; Kramm CM; Golanov A; Capper D; von Deimling A; Pfister SM; Jones DTW Acta Neuropathol; 2017 Sep; 134(3):507-516. PubMed ID: 28401334 [TBL] [Abstract][Full Text] [Related]
15. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528 [TBL] [Abstract][Full Text] [Related]
16. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and Molecular Characteristics of Bae H; Lee B; Hwang S; Lee J; Kim HS; Suh YL Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255255 [TBL] [Abstract][Full Text] [Related]
18. Predictive value of MGMT promoter methylation on the survival of TMZ treated Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600 [TBL] [Abstract][Full Text] [Related]
19. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284 [TBL] [Abstract][Full Text] [Related]
20. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients. Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]